Group 1: Company Overview - Yifan Xinfu Pharmaceutical Co., Ltd. is actively engaging in investor relations activities to provide insights into its operations and strategic direction [1]. - The company is located in Hefei, Anhui Province, and the meeting took place on May 6, 2015 [1]. Group 2: Industry Position and Strategy - The company is focused on the healthcare industry, with ongoing efforts to adapt to national policies and explore effective collaboration models [2]. - Future development in the pharmaceutical sector is centered around innovation and targeted product acquisitions [2]. Group 3: Product Development and Pricing - Yifan Xinfu aims to strengthen its core business in the pantothenic acid series while also developing biodegradable materials [2]. - The recent price drop of pantothenic acid products is a strategic decision based on market conditions, with the company expressing a willingness to increase market share [2]. - The impact of drug price deregulation is expected to be minimal in the short term, but long-term effects may influence companies relying on individually priced products for profit [2].

Group 1: Price Trends and Market Conditions - The recent global market has seen an upward trend in the prices of vitamin products, including calcium pantothenate (vitamin B5), which was at a low price point in 2015 and is expected to rise [2] - The tightening of domestic environmental regulations may have led to some manufacturers being unable to fully release production capacity, resulting in a market characterized by tight supply and increased production costs [2] - The company anticipates that the price of calcium pantothenate will continue to rise in the future, although the duration and extent of the increase are uncertain and ultimately determined by market conditions [2] Group 2: Production and Capacity - The total production capacity for the company's pantothenic acid series products is 12,000 tons per year [2] - The company will decide on order placements based on market conditions and actual production situations, with prices generally following market trends [2] Group 3: Strategic Development - The company's future strategic focus includes three main areas: pharmaceutical raw materials, drug formulations, and the healthcare sector [2] - The company aims to enhance innovation and promote business integration and upgrading while achieving some success in internationalization through strategies like "going out" and "bringing in" [3] - In developing regions, the company plans to establish local factories to supply domestic products, while in developed regions like Europe and the U.S., it will pursue acquisitions of international pharmaceutical companies to expand its global market presence [3]

Group 1: Product Pricing and Market Trends - The price of calcium pantothenate is expected to rise due to a general upward trend in vitamin product prices globally [2] - In 2015, the price of vitamin B5 (calcium pantothenate) was at a low level, indicating potential for upward movement [2] - Strict domestic environmental regulations may have limited production capacity for some manufacturers, leading to a tight supply and increased production costs [2] - The company's total production capacity for pantothenic acid series products is 12,000 tons per year [2] Group 2: Biodegradable Materials - The company launched a fully biodegradable materials project in 2007, featuring proprietary technology and the first continuous production facility in China with a capacity of 10,000 tons [3] - The biodegradable products have gained recognition from customers in Europe and the United States, and the company is the drafting unit for national standards [3] - The products are primarily exported, but domestic demand is expected to grow as environmental regulations become stricter [3] Group 3: Healthcare Development Strategy - The company aims to establish a hospital management system in Anhui within 3-5 years, starting with the management of county-level hospitals [3] - The strategy includes building high-end hospitals and a national chain for specialized treatments, focusing on chronic disease management [3] - The company has initiated its healthcare business by partnering with top medical institutions in Anhui and successfully managing a county hospital [4] Group 4: Future Business Strategy - The company’s strategic focus post-restructuring includes pharmaceutical raw materials, drug formulations, and healthcare sectors [4] - Plans for domestic integration of product lines and international expansion through local manufacturing in underdeveloped regions and acquisitions in developed markets are outlined [4]

Group 1: Company Overview - Yifan Xinfu Pharmaceutical Co., Ltd. is actively engaging with institutional investors to discuss various aspects of its business [2] - The company is led by Chairman and General Manager Cheng Xianfeng, along with other key executives [2] Group 2: Product and Market Insights - The price of the company's product, calcium pantothenate, remains stable and is expected to rise for Q3 orders [3] - The acquisition of DHY Company has been completed, and ongoing projects are progressing as planned, with F627 entering Phase III clinical trials in 40 centers across 13 countries [3][4] Group 3: Financial Activities - The company plans to issue non-public A-shares, pending approval from the China Securities Regulatory Commission, with a target issuance within six months after receiving the approval [4] - Multiple institutions have expressed interest in participating in the upcoming share issuance [4] Group 4: Business Development and Strategy - The company aims to maintain steady growth in its original business while integrating new acquisitions, with two newly established subsidiaries already obtaining GMP certification [4][5] - The company is adapting to industry changes such as the "two-invoice system" and "VAT reform," viewing these as opportunities for compliant and legal operations [5] Group 5: Healthcare Sector Engagement - Yifan Xinfu is cautiously entering the healthcare sector through partnerships, having successfully signed contracts with two managed hospitals [5]

Group 1: Company Overview - Yifan Xinfu Pharmaceutical Co., Ltd. is involved in strategic cooperation with Jianenlong, focusing on innovation and international market strategies [2][3]. - The major shareholder remains unchanged post-transaction, indicating a financial investment completion [3]. Group 2: Core Competencies - Jianenlong's core competencies include advanced technology and a strong management team, with two major platforms for intellectual property protection [3]. - The company has established a cGMP-compliant industrialization factory according to FDA standards and is the first Chinese biotech firm to conduct Phase II clinical trials in the U.S. [3]. Group 3: Financial Insights - Jianenlong has invested over $80 million since its establishment and requires an additional $200 million in the next 2-3 years for future financing [4]. - The G-CSF project, originally developed by Amgen, is expected to generate a market share of $6 billion annually in Europe and the U.S., with long-acting products accounting for 80% of that market [4]. Group 4: Market Potential - The orphan drug project F-652 is projected to reach a market capacity of $1-1.2 billion, benefiting from shorter clinical timelines and faster approval processes [4].

Group 1: Company Performance - The company achieved a revenue of 1.732 billion CNY in the first half of 2016, representing a year-on-year growth of 42.16% [4] - The net profit attributable to shareholders was 364.27 million CNY, with a year-on-year increase of 113.15% [4] - The raw material drug segment showed significant profit growth, contributing to the overall profit increase [4] Group 2: Product and Market Developments - The price of calcium pantothenate is stable and expected to rise slightly in the third quarter, with tight inventory levels [3] - The company acquired a 53.57% stake in Anhui Wanhua Pharmaceutical, primarily to leverage overseas sales channels for vitamin K1 [3] - The company’s agent product, Cefoperazone, showed steady revenue growth in the pharmaceutical formulation segment [5] Group 3: Research and Development - The DHY company's research projects are progressing as planned, with F627 entering international Phase III clinical trials [4] - Other in-development products are also advancing through various clinical stages [4] Group 4: Future Strategy - The company’s future plans focus on integration, innovation, and internationalization [6] - Plans include establishing and acquiring multiple pharmaceutical companies to enhance synergy and resource complementarity [6] - The company aims to enhance R&D capabilities through the introduction of high-tech talent and collaboration [6]

Financial Performance - Revenue for Q3 2022 was ¥959,518,634.11, a decrease of 5.94% year-over-year, and a total revenue of ¥2,728,866,329.74 for the year-to-date, down 19.68% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2022 was ¥42,696,040.25, a decline of 45.00% year-over-year, with year-to-date net profit of ¥203,256,070.64, down 30.10%[3]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥24,925,435.23, a decrease of 62.08% year-over-year, and year-to-date was ¥130,283,488.50, down 47.89%[3]. - The company reported a significant decrease in pharmaceutical service revenue, which contributed to the decline in net profit[3]. - The company reported a net profit margin decline due to reduced operating revenue and increased costs, impacting overall profitability[22]. - The total revenue for Q3 2022 was approximately 753.19 million, an increase from 607.22 million in Q3 2021, representing a growth of about 24%[24]. - The net profit for Q3 2022 was approximately 150.26 million, down from 242.33 million in Q3 2021, indicating a decrease of about 38%[24]. - Operating profit for Q3 2022 was approximately 186.75 million, compared to 277.14 million in Q3 2021, reflecting a decline of about 33%[24]. - The basic earnings per share for Q3 2022 was 0.16, compared to 0.24 in Q3 2021, a decline of about 33%[25]. - The total comprehensive income attributable to the parent company's owners for Q3 2022 was approximately 196.35 million, compared to 204.24 million in Q3 2021, a decrease of about 4%[25]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥12,693,749,219.29, an increase of 4.35% from the end of the previous year[3]. - Total assets increased to approximately $12.69 billion, up from $12.17 billion year-over-year, reflecting a growth of about 4.3%[21]. - Total liabilities rose to approximately $3.57 billion, compared to $3.39 billion in the previous year, indicating an increase of about 5.5%[21]. - Non-current assets totaled approximately $8.77 billion, an increase from $8.58 billion, showing a growth of about 2.2%[21]. Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥273,207,235.15, a decrease of 16.68% compared to the previous year[3]. - Cash flow from operating activities for Q3 2022 was approximately 273.21 million, down from 327.90 million in Q3 2021, a decrease of about 17%[27]. - Cash flow from investment activities showed a net outflow of approximately 400.31 million in Q3 2022, compared to a net outflow of 659.89 million in Q3 2021, improving by about 39%[27]. - The company’s cash and cash equivalents stood at approximately $1.32 billion, slightly down from $1.34 billion[19]. - The cash and cash equivalents at the end of Q3 2022 amounted to approximately 1.10 billion, an increase from 710.12 million at the end of Q3 2021[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 52,006[9]. - The largest shareholder, Cheng Xianfeng, holds 40.50% of the shares, totaling 496,526,307 shares, with 66,500,000 shares pledged[9]. - The top ten shareholders hold a total of 124,131,577 unrestricted shares[12]. - Cheng Xianfeng's unrestricted shares amount to 124,131,577, while Hong Kong Central Clearing Limited holds 19,077,392 unrestricted shares[12]. - The company has not identified any other related party relationships among shareholders beyond those disclosed[13]. Government Support and Investments - The company received government subsidies amounting to ¥80,146,605.63 year-to-date, which is an increase of 134.61% compared to the previous year[8]. - Evive Biotech Ltd. plans to issue common stock at $7.2225 per share, with Sino Biopharmaceutical Limited investing $20 million for 2,769,132 shares and committing to invest at least $10 million in future financing[18]. - The total investment from Yifan Pharmaceutical (Hong Kong) Co., Ltd. amounts to $50 million for 6,922,831 shares, bringing the total investment in Evive to $70 million[18]. Operational Changes - The company’s long-term borrowings increased by 40.94% to ¥1,029,599,250.26 due to adjustments in financing structure[7]. - The company reported a 34.12% decrease in operating costs year-to-date, totaling ¥1,331,405,844.19, primarily due to reduced promotional service costs[8]. - The company completed the registration capital change, reducing it from RMB 1,234,106,077 to RMB 1,226,024,827[17]. - The employee stock ownership plan raised RMB 78.5 million, with 70 participants, and purchased 3,960,900 shares at an average price of approximately RMB 10.192 per share[15]. - The company has implemented a stock repurchase plan for restricted stock from 2019, with completion reported on July 29, 2022[14]. Regulatory Approvals - The company’s subsidiary received a drug registration certificate for lactulose oral solution on August 17, 2022[16]. - The company’s subsidiary obtained a registration approval for traditional Chinese medicine from the Singapore Health Sciences Authority in September 2022[16].

Financial Performance - Yifan Pharmaceutical's financial report is guaranteed to be true, accurate, and complete by its management team[2]. - The company's revenue for the first half of 2022 was CNY 1,769,347,695.63, a decrease of 25.58% compared to CNY 2,377,403,852.30 in the same period last year[13]. - Net profit attributable to shareholders for the same period was CNY 160,560,030.39, down 24.67% from CNY 213,141,089.54 year-on-year[13]. - The net profit after deducting non-recurring gains and losses was CNY 105,358,053.27, representing a decline of 42.82% compared to CNY 184,269,117.63 in the previous year[13]. - The net cash flow from operating activities was CNY 183,810,575.85, a decrease of 18.71% from CNY 226,113,089.99 in the same period last year[13]. - Basic earnings per share were CNY 0.13, down 23.53% from CNY 0.17 in the previous year[13]. - Total assets as of June 30, 2022, were CNY 12,475,973,066.21, an increase of 2.56% from CNY 12,165,124,976.56 at the end of the previous year[13]. - Net assets attributable to shareholders were CNY 8,628,473,676.89, up 1.09% from CNY 8,535,174,993.28 at the end of the previous year[13]. - The company reported a total non-operating income of ¥55,201,977.12, primarily due to the write-off of uncollectible amounts during the reporting period[17]. - The company achieved a revenue of CNY 1,769.35 million in the first half of 2022, a decrease of 25.58% compared to the same period last year[36]. Risk Management - The company has not identified any significant risks impacting its operations during the reporting period[2]. - The management highlighted various potential risks including COVID-19, R&D underperformance, and international operational risks[2]. - The company has a comprehensive risk management strategy in place to address various operational challenges[2]. - The company faces risks from the ongoing COVID-19 pandemic, which may adversely affect overseas R&D, production, sales, and supply chain construction[69]. - The company is exposed to risks related to drug development not meeting expectations, including the potential for clinical trial failures and the conversion of capitalized development expenses to operating expenses[70]. - The company is addressing performance volatility risks due to fluctuating prices of key products like Vitamin B5, aiming to enhance pharmaceutical business performance[72]. - The company is adapting to centralized procurement policies that may pressure drug prices and affect domestic sales, while increasing the proportion of international revenue[73]. - The company is closely monitoring exchange rate fluctuations, which have significantly impacted profitability due to mismatched foreign currency assets and liabilities[75]. - The company plans to enhance risk management by optimizing foreign currency allocation and utilizing financial instruments to hedge against exchange rate risks[76]. - International operations are facing risks from geopolitical tensions, particularly the ongoing US-China trade disputes, which may affect revenue and profit from overseas businesses[77]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through R&D[2]. - The company is committed to ongoing research and development in the pharmaceutical sector to drive future growth[18]. - The company completed the registration of three products and submitted three new drug applications during the reporting period, with a total of 51 projects still under development[43]. - The company has established partnerships for the sale of certain products, enhancing its market reach and distribution capabilities[19]. - The F-627 product, aimed at treating chemotherapy-induced neutropenia, has received regulatory acceptance in China and is undergoing clinical trials in multiple regions[37]. Market Conditions - The pharmaceutical industry is entering a new phase of high-quality development, driven by innovation and modernization of the industrial chain, but is facing challenges such as declining profits and market growth slowing down[23]. - In the first half of 2022, the pharmaceutical manufacturing industry achieved revenue of CNY 1,400.78 billion, a year-on-year decline of 0.6%, which is 9.7 percentage points lower than the overall level of large-scale industrial enterprises[23]. - The total profit of the pharmaceutical manufacturing industry in the first half of 2022 was approximately CNY 220.95 billion, down 27.6% year-on-year, which is 28.6 percentage points lower than the overall level of large-scale industrial enterprises[23]. - The vitamin industry is experiencing a decline in market conditions due to oversupply, weak terminal consumption growth, and disordered competition among small manufacturers[25]. - The company’s main products, vitamin B5 and its derivatives, are crucial in the vitamin market, which is largely driven by animal nutrition and food additives[26]. Environmental Compliance - The company is committed to adhering to local environmental standards and enhancing safety measures in response to global carbon emission policies[78]. - The company achieved a compliance rate of 100% across all monitored pollutants in the reporting period[87][88]. - The company has implemented effective pollution prevention facilities, ensuring operational compliance with environmental regulations[88]. - The wastewater treatment facility has a processing capacity of 3,000 t/d and has been in operation since November 2002, with stable performance[89]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, with multiple drills conducted to enhance emergency handling capabilities[95]. Shareholder Information - Yifan Pharmaceutical reported no cash dividends or stock bonuses for the period[3]. - The company has not reported any significant impairment risks for its overseas assets[53]. - The company has not engaged in any related party transactions during the reporting period[103]. - The company has maintained a clean record with no non-operating fund occupation by major shareholders or related parties[101]. - The total number of ordinary shareholders at the end of the reporting period was 48,451, representing 5% of the total shares[124].

Financial Performance - The company's revenue for Q1 2022 was ¥905,920,591.79, a decrease of 24.53% compared to ¥1,200,337,373.23 in the same period last year[2] - Net profit attributable to shareholders was ¥121,266,909.58, down 8.30% from ¥132,244,842.10 year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥76,821,416.28, reflecting a significant decline of 31.90% from ¥112,814,160.06 in the previous year[3] - The total profit for Q1 2022 was approximately ¥135.57 million, a decrease of 8.5% compared to ¥147.57 million in Q1 2021[22] - The net profit attributable to the parent company was approximately ¥121.27 million, down from ¥132.24 million, representing a decline of 8.3% year-over-year[22] - The company's net profit for Q1 2022 was CNY 124,239,046.87, a decrease of 7.9% compared to CNY 134,304,706.57 in Q1 2021[21] - The company's total comprehensive income for Q1 2022 was approximately ¥89.54 million, down from ¥114.53 million in Q1 2021, indicating a decline of 21.8%[22] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥46,018,343.12, a drastic decrease of 130.90% compared to ¥148,929,731.56 in the same period last year[4] - The operating cash flow for Q1 2022 was negative at approximately -¥46.02 million, compared to a positive cash flow of ¥148.93 million in the same period last year[23] - Total cash inflow from operating activities was approximately ¥1.01 billion, a decrease of 17.2% from ¥1.22 billion in Q1 2021[23] - The company reported a net cash outflow from investing activities of approximately -¥145.91 million, an improvement from -¥217.93 million in Q1 2021[24] - Cash and cash equivalents at the end of Q1 2022 totaled approximately ¥1.02 billion, slightly down from ¥1.03 billion at the end of Q1 2021[24] - The company's cash and cash equivalents increased to CNY 1,500,808,136.01 from CNY 1,336,143,759.93 at the beginning of the year, representing a growth of 12.3%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,499,765,833.99, representing a 2.75% increase from ¥12,165,124,976.56 at the end of the previous year[3] - The total assets of the company reached CNY 12,499,765,833.99, an increase from CNY 12,165,124,976.56 at the beginning of the year, marking a growth of 2.7%[20] - The total liabilities increased to CNY 3,622,045,879.06 from CNY 3,390,566,493.65, representing a rise of 6.8%[20] Shareholder Information - The top shareholder, Cheng Xianfeng, holds 40.23% of the shares, amounting to 496,526,307 shares[10] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 1.65% of the shares, totaling 20,370,446 shares[10] - Cheng Xianfeng and several investment funds are identified as acting in concert, indicating a coordinated shareholder strategy[12] - The top ten shareholders hold a total of 124,131,577 shares of common stock, representing a significant portion of the company's equity[11] Operating Costs and Expenses - The company's gross profit margin decreased due to a shift in revenue structure, with a 40.76% reduction in operating costs to ¥427,472,846.50 from ¥721,608,037.10[8] - Total operating costs for Q1 2022 were CNY 815,202,981.81, down 23.5% from CNY 1,065,298,825.32 in Q1 2021[21] - Financial expenses surged by 388.98% to ¥21,742,252.26, primarily due to increased interest expenses and foreign exchange losses[8] - Research and development expenses for Q1 2022 were CNY 38,302,629.24, slightly down from CNY 40,513,368.64 in the previous year[21] Product Development and Licensing - The company received drug registration certificates for multiple products, including Ammonium Bromide Injection on January 7, 2022[14] - The company signed an exclusive licensing agreement for the product F-627 with Apogepha Arzneimittel GmbH, involving a non-refundable advance of $400,000 and potential milestone payments up to $37.5 million[17] - The company’s subsidiary, Hefei Yifan Biopharmaceutical Co., received a registration acceptance notice for Dopamine Hydrochloride Injection on January 11, 2022[14] - The company’s subsidiary, Liao Ning Yifan Pharmaceutical Co., received a registration acceptance notice for Tirofiban Hydrochloride Injection on January 24, 2022[14] - The company’s subsidiary, Yifan You Sheng Mei Te Pharmaceutical Technology Co., passed the consistency evaluation for Cefuroxime Sodium Injection[15] Stock and Incentives - The company has initiated a stock incentive plan, with the second vesting period approved on January 4, 2022[13] - Basic earnings per share for Q1 2022 were ¥0.10, compared to ¥0.11 in Q1 2021, reflecting a decrease of 9.1%[23] - The weighted average return on net assets was 1.41%, down from 1.55% in the previous year[3] - The company recorded other comprehensive income after tax of approximately -¥14.91 million, worsening from -¥3.69 million in the previous year[22]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-over-year increase of 15%[9]. - The net profit for 2021 was 200 million RMB, which is a 10% increase compared to the previous year[9]. - The company's operating revenue for 2021 was ¥4,409,035,585.85, a decrease of 18.36% compared to 2020[14]. - The net profit attributable to shareholders for 2021 was ¥278,398,951.02, down 71.25% from the previous year[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥220,375,153.57, a decline of 74.41% year-over-year[14]. - The diluted earnings per share for 2021 was ¥0.23, down 70.89% from ¥0.79 in 2020[15]. - The total assets at the end of 2021 were ¥12,165,124,976.56, an increase of 4.54% from the end of 2020[15]. - The net assets attributable to shareholders at the end of 2021 were ¥8,535,174,993.28, up 1.13% from the previous year[15]. - The company achieved operating revenue of 440,903.56 million yuan, a decrease of 18.36% year-on-year, and net profit attributable to shareholders of 27,839.90 million yuan, down 71.25% year-on-year[63]. Revenue Guidance and Growth Targets - The company has set a revenue guidance of 1.5 billion RMB for 2022, indicating a growth target of 25%[9]. - The company reported a significant decline in net profit in Q4 2021, primarily due to goodwill impairment testing and decreased revenue from pharmaceutical services[18]. - The company plans to explore potential mergers and acquisitions to strengthen its market position in the pharmaceutical industry[8]. Research and Development - New product F-627, an injectable drug, is currently in the research phase and is expected to enter clinical trials in 2022[8]. - The company has invested 50 million RMB in R&D for new technologies in 2021, focusing on innovative drug delivery systems[8]. - The company has established a dual-molecule research platform, DiKineTM, to develop innovative biopharmaceuticals for the global market[60]. - The company is developing innovative drugs for the overseas market, with projects F-627 and F-652 having completed clinical trials and submitted for approval in multiple regions[92]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, with plans to establish partnerships in three new countries by the end of 2022[8]. - The company has signed commercialization cooperation agreements in China, Greece, Cyprus, and Germany, expanding its market presence[63]. - The company is actively pursuing new product registrations and has submitted applications for four new generic drugs to the US FDA[67]. Risks and Challenges - The company has outlined various risks that may impact its operations, including COVID-19, research and development underperformance, and international business risks[2]. - The company acknowledges the risk of research and development projects not meeting expectations, which could lead to financial losses if clinical trials fail or are delayed[133]. - The company is addressing the risk of performance volatility in its Vitamin B5 product line due to market competition and supply-demand dynamics, while also expanding its pharmaceutical business[134]. Environmental Management - The company is committed to environmental management and pollution control, aligning with national policies on carbon peak action and green development[40]. - The wastewater treatment facility has a processing capacity of 3,000 tons per day and has been in operation since November 2002, with stable performance[198]. - The company has implemented pollution control facilities for both wastewater and flue gas, ensuring compliance with environmental standards[198]. Corporate Governance - The company has established a robust internal control system, revising over 20 regulations to enhance governance and operational standards[146]. - The company emphasizes strict compliance with laws and regulations regarding related transactions and significant investments[194]. - The company has maintained a clear separation from its controlling shareholder in both operational and financial aspects, with no interference in fund usage[148]. Employee Management - The employee compensation structure includes fixed salaries, performance bonuses, and benefits, aimed at enhancing employee satisfaction and loyalty[176]. - The company has conducted various training programs for employees, focusing on skill enhancement and organizational performance improvement[177]. - The total number of employees at the end of the reporting period was 4,285, with 60 in the parent company and 4,225 in major subsidiaries[175]. Product Portfolio - Key products include Zometa for treating bone damage in cancer patients and Thymosin α1 for immune modulation in cancer and hepatitis treatment, with both domestic and international sales strategies[42]. - The company has a total of 336 approved drug products domestically, with 41 exclusive varieties, highlighting its diverse product portfolio[58]. - The company’s vitamin B5 products are marketed globally as essential additives in feed and food industries[45]. Financial Management - The company has implemented a centralized management platform for overseas funds, enhancing the efficiency of domestic and international fund flows[75]. - The company reported a financial liability of ¥28,631.90 at the end of the reporting period, with an increase of ¥6,936.77 during the period[102]. - The company has not engaged in any related party transactions that would involve the controlling shareholder misusing company funds[148].